SCYL2 Antibody

What is SCYL2 and why is it important to study?

SCYL2, also known as CVAK104 (coated vesicle-associated kinase of 104 kDa), is a protein that functions as a component of the AP2-containing clathrin coat involved in regulating clathrin-dependent trafficking at the plasma membrane, trans-Golgi network (TGN), and endosomal systems . SCYL2 plays critical roles in:

• Vesicular trafficking between cellular compartments

• Probable kinase activity toward the beta2-subunit of the plasma membrane adapter complex AP2

• Protection of CA3 pyramidal neurons from excitotoxicity during functional maturation

• Regulation of excitatory receptors at synapses, which is essential for neuronal function and brain development

Research on SCYL2 provides valuable insights into fundamental cellular processes and may help understand neurological disorders related to vesicular trafficking dysfunction.

What applications are SCYL2 antibodies validated for?

SCYL2 antibodies have been validated for multiple experimental applications:

When selecting an antibody, researchers should prioritize products with validation data specific to their intended application and sample type .

What species reactivity has been confirmed for SCYL2 antibodies?

Various commercial SCYL2 antibodies demonstrate reactivity with:

• Human SCYL2 (most widely validated)

• Mouse SCYL2 (widely validated)

• Rat SCYL2 (validated in some antibodies)

Researchers should verify species cross-reactivity through published validation studies, especially when working with model organisms. Western blot validation data typically shows a band at approximately 104 kDa, corresponding to the expected molecular weight of SCYL2 .

How should SCYL2 antibodies be stored and handled?

For optimal performance and longevity of SCYL2 antibodies:

• Store at -20°C as recommended by manufacturers

• Most products remain stable for one year after shipment when properly stored

• Aliquoting is generally unnecessary for -20°C storage, but may be beneficial for frequently used antibodies to avoid freeze-thaw cycles

• Most SCYL2 antibodies are supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

• Some products (20μL sizes) may contain 0.1% BSA as a stabilizer

Always follow specific manufacturer recommendations, as formulations may vary between products.

What validation criteria should be applied when selecting a SCYL2 antibody for critical research applications?

According to established validation frameworks, researchers should evaluate SCYL2 antibodies using multiple independent validation strategies :

• Orthogonal validation: Compare SCYL2 protein levels detected by antibody with mRNA expression or mass spectrometry data across multiple samples. Validation requires:

  • At least a fivefold difference in expression levels between samples

  • Strong correlation between antibody signal and orthogonal measurements

• Genetic validation: Confirm antibody specificity using:

  • siRNA knockdown experiments showing reduction in signal (>25% reduction required)

  • Knockout models with complete signal elimination

  • Overexpression systems showing increased signal

• Independent antibody validation: Compare staining patterns from multiple antibodies targeting different epitopes of SCYL2

• Capture mass spectrometry: Validate by cutting out gel bands corresponding to the observed WB signal and confirming SCYL2 peptide presence by MS analysis

Rigorous validation improves reliability and reproducibility of SCYL2-focused research projects.

How can researchers troubleshoot inconsistent SCYL2 antibody performance across different cellular contexts?

Inconsistent antibody performance may result from several factors:

• Expression level variations: SCYL2 expression varies across tissues and cell lines. Verify expression using transcriptomic data before experiments .

• Post-translational modifications: SCYL2 may undergo modifications affecting epitope accessibility. Consider:

  • Phosphorylation state (SCYL2 is a putative kinase)

  • Protein-protein interactions masking epitopes

  • Conformational changes in different cellular compartments

• Sample preparation effects:

  • For WB: Optimize lysis buffers and denaturation conditions

  • For IHC: Test different antigen retrieval methods (both TE buffer pH 9.0 and citrate buffer pH 6.0 have been effective)

• Cross-reactivity: Some antibodies may detect related proteins. Validate specificity using genetic approaches .

Methodological solution: Perform side-by-side comparisons of multiple SCYL2 antibodies using consistent protocols and include appropriate positive and negative controls.

What methodological approaches best demonstrate SCYL2 colocalization with vesicular trafficking components?

For robust colocalization studies:

• Dual immunofluorescence protocol:

  • Fix cells with 4% paraformaldehyde (10 min, RT)

  • Permeabilize with 0.1% Triton X-100 (5 min, RT)

  • Block with 3% BSA in PBS (1 hour, RT)

  • Co-incubate with SCYL2 antibody (e.g., Proteintech 12325-1-AP, 1:200) and markers for:

    • Clathrin heavy chain (CHC)

    • Adaptor protein complexes (AP1, AP2, AP3)

    • Trans-Golgi network (TGN) markers

    • Endosomal markers

• Biochemical interaction verification:

  • Co-immunoprecipitation to detect interactions with trafficking components

  • Pull-down assays with tagged SCYL2 have successfully demonstrated interactions with CHC1, VTI11, and VTI12

• Advanced imaging approaches:

  • Super-resolution microscopy for precise colocalization analysis

  • Live-cell imaging with fluorescently-tagged SCYL2 to track dynamics

Quantitative colocalization analysis using Pearson's or Mander's coefficients provides statistical rigor to these studies.

How does SCYL2 antibody performance compare in neuronal versus non-neuronal tissues given its specialized neuronal functions?

SCYL2 antibodies show distinct performance characteristics across tissue types:

• Neuronal tissue considerations:

  • SCYL2 has been validated in mouse brain and cerebellum tissues

  • Critical for protecting CA3 pyramidal neurons from excitotoxicity

  • May require specialized fixation protocols for preservation of neuronal structures

• Methodological differences:

  • Neuronal tissues: Perfusion fixation recommended before IHC

  • Non-neuronal tissues: Standard fixation protocols generally sufficient

• Expression level variations:

  Tissue Type	SCYL2 Expression	Antibody Performance Notes
  Brain	High	Strong, specific signal in WB and IHC
  Heart	Moderate	Validated in WB applications
  Kidney	Low-moderate	Validated in WB applications
  Uterus	Variable	Positive WB detection reported

• Optimization requirements:

  • For neuronal tissues: Use TE buffer pH 9.0 for antigen retrieval (alternative: citrate buffer pH 6.0)

  • For cell lines: HEK-293T, NIH/3T3, Jurkat, HeLa, and HepG2 cells have been validated as positive controls

What methodological approaches can resolve conflicting SCYL2 antibody results across different studies?

When facing contradictory results:

• Antibody standardization protocol:

  • Implement enhanced validation using multiple approaches (orthogonal, genetic, etc.)

  • Assign reliability scores based on validation criteria:

    • Enhanced: Meets strict criteria for orthogonal or independent antibody validation

    • Supported: Shows RNA consistency or paired antibody similarity

    • Approved: Has RNA consistency but conflicting literature

    • Uncertain: Shows low consistency or conflicting data

• Cross-laboratory validation:

  • Exchange and blind-test antibodies between laboratories

  • Standardize protocols including sample preparation, antibody dilution, and detection methods

• Data integration strategy:

  • Compare results from multiple antibodies targeting different SCYL2 epitopes

  • Triangulate findings with orthogonal techniques (RT-PCR, MS proteomics)

  • Consider genetic models (knockdown/knockout) as definitive controls

This methodological framework helps establish consensus across divergent findings.

How can researchers quantitatively assess SCYL2 expression changes in disease models?

For quantitative evaluation of SCYL2 expression:

• Western blot quantification protocol:

  • Use validated SCYL2 antibodies at optimized dilutions (e.g., 1:5000-1:50000)

  • Include housekeeping protein controls (β-actin, GAPDH)

  • Implement a standard curve using recombinant SCYL2 protein

  • Analyze with densitometry software, normalizing to loading controls

  • Apply statistical analysis for between-group comparisons

• IHC/IF quantification methodology:

  • Use consistent acquisition parameters

  • Implement automated thresholding and region-of-interest analysis

  • Apply cell-by-cell quantification when possible

  • Consider multiple tissue sections and biological replicates

• Multi-modal validation approach:

  • Correlate protein levels (antibody-based) with mRNA expression

  • Confirm changes using at least two independent SCYL2 antibodies

  • Validate functional consequences through interaction studies or activity assays

This comprehensive quantitative framework enables reliable assessment of SCYL2 alterations in disease contexts.